-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
Healthcare AI Shakeout: Health Systems Plan to Cut AI Vendors Nearly in Half by 2028, Black Book Finds
-
Sparta Capital Ltd. Announces Resumption of Trading
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
CORRECTION FROM SOURCE: Nixxy Announces 1-for-20 Reverse Stock Split
-
Olenox Secures Texas Pipeline Operating Permit, Clearing Path for Initial 4 MW Power Deployment
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
EU watchdog backs Sanofi Covid booster jab
The EU on Thursday approved a Covid booster vaccine by French drug maker Sanofi and Britain's GSK after it gave positive results against the Omicron variant in trials.
The approval of the "next generation" jab by the European Medicines Agency (EMA) is a shot in the arm for Sanofi and GSK, which have lagged behind rivals in offering a vaccine.
The VidPrevtyn Beta jab could be used as a booster in adults previously given mRNA jabs like those from Pfizer/BioNTech and Moderna, or viral vector vaccines made by AstraZeneca and Johnson & Johnson, the EMA said.
"A booster dose of VidPrevtyn Beta is expected to be at least as effective as Comirnaty (Pfizer's vaccine) at restoring protection against Covid-19," the Amsterdam-based EMA said.
A trial of 162 adults given the Sanofi-GSK booster showed that it triggers a higher production of antibodies against the Omicron BA.1 subvariant than Pfizer's jab, the regulator said.
A second study restored immunity in 627 adults who received other vaccines for their first course of jabs.
Sanofi said it was ready to start its first shipments of the booster in Britain and the EU, in line with advance contracts for 70 million doses.
"Today's approval validates our research in developing a novel solution for the Covid-19 pandemic," Thomas Triomphe, Sanofi executive vice president for vaccines, said.
The vaccine combines a Sanofi-developed antigen based on the Beta variant, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.
- End of a long road -
Sanofi and GSK developed the jab at the same time that they are waiting for regulatory approval for their first-generation vaccine.
The approval marks the end of a long journey for Sanofi to bring a Covid vaccine to market. The French pharma giant, considered to be a world leader on vaccines, has come under huge scrutiny at home for failing to roll out a Covid jab earlier.
The firm vowed to produce a billion vaccine doses in 2021, only for a dosage problem during clinical trials to send its researchers back to the drawing board. It also tried to develop a vaccine based on mRNA technology, only to abandon that plan as well.
While it struggled, Pfizer/BioNTech and Moderna brought their vaccines to market at a pace never before seen in history. Both vaccines were approved nearly two full years before Sanofi's breakthrough on Thursday.
"It is, it must be recognised, a failure... compared to the speed that was needed," Sanofi chairman Serge Weinberg told a shareholders' meeting in May.
While Sanofi has finally managed to get a Covid vaccine approved, the question remains about how much demand remains in an already crowded market.
Last week frontrunner Pfizer raised the annual sales forecast for its vaccine to $36 billion on the back of new deals for boosters.
Moderna meanwhile slashed the sales forecast for its own vaccine by $2-$3 billion dollars due to shipment delays.
On Thursday, French-Austrian biotech Valneva announced it will cut up to a quarter of its workforce.
Valneva became the first French firm to get a Covid vaccine approved by the EMA in June. It suspended production a month later, however, after the EU slashed its initial order of 60 million doses to just 1.25 million.
E.Flores--AT